Stock INCY INCYTE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
57.33 USD -0.57% Intraday chart for Incyte Corporation -5.43% -8.70%
Jul. 02 S&P 500, Nasdaq Close at Record Highs After Fed Chair Powell's Comments MT
Jul. 02 S&P 500, Nasdaq Close at Record Highs After Fed Chair Powell's Comments MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 18,808 19,048 16,213 17,869 14,072 12,891 - -
Enterprise Value (EV) 1 16,742 17,535 13,865 14,630 10,416 9,059 7,486 5,992
P/E ratio 42.6 x -64 x 17.2 x 52.8 x 23.7 x 16.4 x 13.7 x 10.8 x
Yield - - - - - - - -
Capitalization / Revenue 8.71 x 7.14 x 5.43 x 5.26 x 3.81 x 3.16 x 2.87 x 2.58 x
EV / Revenue 7.76 x 6.58 x 4.64 x 4.31 x 2.82 x 2.22 x 1.66 x 1.2 x
EV / EBITDA 36.7 x -82.8 x 21.5 x 24.5 x 14.8 x 9.57 x 5.69 x 3.44 x
EV / FCF 26.5 x -56.2 x 24.4 x 16.4 x 22.4 x 10.1 x 7.01 x 4.51 x
FCF Yield 3.78% -1.78% 4.1% 6.1% 4.45% 9.87% 14.3% 22.2%
Price to Book 7.22 x 7.26 x 4.32 x 4.09 x 2.71 x 2.25 x 1.8 x 1.48 x
Nbr of stocks (in thousands) 215,397 218,996 220,891 222,475 224,109 224,855 - -
Reference price 2 87.32 86.98 73.40 80.32 62.79 57.33 57.33 57.33
Announcement Date 2/13/20 2/9/21 2/8/22 2/7/23 2/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,159 2,667 2,986 3,395 3,696 4,080 4,498 5,001
EBITDA 1 456.5 -211.9 643.6 597.7 703.2 946.4 1,316 1,740
EBIT 1 402 -263.7 585.8 579.4 620.5 1,039 1,330 1,662
Operating Margin 18.62% -9.89% 19.62% 17.07% 16.79% 25.47% 29.57% 33.23%
Earnings before Tax (EBT) 1 486.8 -232.2 570.4 529.1 834.2 1,064 1,270 1,690
Net income 1 446.9 -295.7 948.6 340.7 597.6 806.8 955.3 1,211
Net margin 20.7% -11.09% 31.76% 10.04% 16.17% 19.77% 21.24% 24.21%
EPS 2 2.050 -1.360 4.270 1.520 2.650 3.505 4.173 5.288
Free Cash Flow 1 632.6 -312 568.5 892.1 464 894.3 1,067 1,329
FCF margin 29.3% -11.7% 19.04% 26.28% 12.56% 21.92% 23.73% 26.58%
FCF Conversion (EBITDA) 138.56% - 88.33% 149.27% 65.99% 94.49% 81.1% 76.41%
FCF Conversion (Net income) 141.55% - 59.93% 261.88% 77.64% 110.85% 111.72% 109.81%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/13/20 2/9/21 2/8/22 2/7/23 2/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 862.9 733.2 911.4 823.3 926.7 808.7 954.6 919 1,013 880.9 1,010 1,053 1,130 1,003 1,142
EBITDA 125.6 - 270.9 155.1 137.9 - 214.1 236.1 - 183.1 - - - - -
EBIT 1 110.7 116.5 254.4 138.4 70.09 24.77 193.8 214.7 187.3 161.2 263.5 289.1 332.2 335.3 406
Operating Margin 12.83% 15.89% 27.92% 16.81% 7.56% 3.06% 20.3% 23.36% 18.48% 18.3% 26.1% 27.45% 29.39% 33.43% 35.55%
Earnings before Tax (EBT) 1 120 70.54 229.4 148.6 80.62 51.86 277.6 233.8 271 236.2 256.8 264.7 359.5 202.4 308.5
Net income 1 563.9 37.99 161.4 112.8 28.46 21.7 203.5 171.3 201.1 169.5 187.9 201.6 265.6 166 252.9
Net margin 65.35% 5.18% 17.71% 13.7% 3.07% 2.68% 21.32% 18.64% 19.84% 19.25% 18.61% 19.14% 23.5% 16.55% 22.15%
EPS 2 2.540 0.1700 0.7200 0.5000 0.1300 0.1000 0.9000 0.7600 0.8900 0.7500 0.8387 0.9073 1.082 0.8600 1.300
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/8/22 5/3/22 8/2/22 11/1/22 2/7/23 5/2/23 8/1/23 10/31/23 2/13/24 4/30/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 2,067 1,513 2,348 3,239 3,656 3,831 5,405 6,898
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 633 -312 568 892 464 894 1,067 1,329
ROE (net income / shareholders' equity) 27.2% -11.4% 29.7% 8.37% 12.5% 15.9% 17.6% 18%
ROA (Net income/ Total Assets) 20.3% -8.46% 22.3% 6.32% 9.47% 12.3% 14% 14.2%
Assets 1 2,205 3,494 4,247 5,387 6,312 6,552 6,831 8,527
Book Value Per Share 2 12.10 12.00 17.00 19.60 23.10 25.50 31.80 38.80
Cash Flow per Share 2 3.270 -0.5700 3.370 4.330 2.200 4.330 5.140 6.910
Capex 1 78.1 187 181 77.8 32.5 38.7 118 152
Capex / Sales 3.62% 7.03% 6.06% 2.29% 0.88% 0.95% 2.62% 3.04%
Announcement Date 2/13/20 2/9/21 2/8/22 2/7/23 2/13/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Incyte Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
57.33 USD
Average target price
72.62 USD
Spread / Average Target
+26.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
INCYTE CORPORATION Stock Incyte Corporation
-8.70% 12.89B
CSL LIMITED Stock CSL Limited
+4.57% 97.7B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+5.66% 41.43B
BIOGEN INC. Stock Biogen Inc.
-12.80% 32.85B
UCB Stock UCB
+80.99% 29.33B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.53% 15.47B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.22% 11.51B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+183.25% 10.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-55.41% 8.97B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.60% 8.97B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. INCY Stock
  4. Financials Incyte Corporation